

Sequence Listing

<110> De Sauvage, Frederic
Grewal, Iqbal
Gurney, Austin L.

<120> TYPE I CYTOKINE RECEPTOR TCCR

<130> P1748R1E

<140> US 10/088,950
<141> 2002-10-20

<150> US 60/160,542
<151> 1999-10-20

<150> PCT/US00/28827
<151> 2000-10-18

<160> 16

<210> 1
<211> 636
<212> PRT
<213> Homo sapiens

<400> 1
Met Arg Gly Gly Arg Gly Ala Pro Phe Trp Leu Trp Pro Leu Pro
1 5 10 15
Lys Leu Ala Leu Leu Pro Leu Leu Trp Val Leu Phe Gln Arg Thr
20 25 30
Arg Pro Gln Gly Ser Ala Gly Pro Leu Gln Cys Tyr Gly Val Gly
35 40 45
Pro Leu Gly Asp Leu Asn Cys Ser Trp Glu Pro Leu Gly Asp Leu
50 55 60
Gly Ala Pro Ser Glu Leu His Leu Gln Ser Gln Lys Tyr Arg Ser
65 70 75
Asn Lys Thr Gln Thr Val Ala Val Ala Ala Gly Arg Ser Trp Val
80 85 90

Ala Ile Pro Arg Glu Gln Leu Thr Met Ser Asp Lys Leu Leu Val
95 100 105

Trp Gly Thr Lys Ala Gly Gln Pro Leu Trp Pro Pro Val Phe Val
110 115 120

Asn Leu Glu Thr Gln Met Lys Pro Asn Ala Pro Arg Leu Gly Pro
125 130 135

Asp Val Asp Phe Ser Glu Asp Asp Pro Leu Glu Ala Thr Val His
140 145 150

Trp Ala Pro Pro Thr Trp Pro Ser His Lys Val Leu Ile Cys Gln
155 160 165

Phe His Tyr Arg Arg Cys Gln Glu Ala Ala Trp Thr Leu Leu Glu
170 175 180

Pro Glu Leu Lys Thr Ile Pro Leu Thr Pro Val Glu Ile Gln Asp
185 190 195

Leu Glu Leu Ala Thr Gly Tyr Lys Val Tyr Gly Arg Cys Arg Met
200 205 210

Glu Lys Glu Glu Asp Leu Trp Gly Glu Trp Ser Pro Ile Leu Ser
215 220 225

Phe Gln Thr Pro Pro Ser Ala Pro Lys Asp Val Trp Val Ser Gly
230 235 240

Asn Leu Cys Gly Thr Pro Gly Gly Glu Glu Pro Leu Leu Leu Trp
245 250 255

Lys Ala Pro Gly Pro Cys Val Gln Val Ser Tyr Lys Val Trp Phe
260 265 270

Trp Val Gly Gly Arg Glu Leu Ser Pro Glu Gly Ile Thr Cys Cys
275 280 285

Cys Ser Leu Ile Pro Ser Gly Ala Glu Trp Ala Arg Val Ser Ala
290 295 300

Val Asn Ala Thr Ser Trp Glu Pro Leu Thr Asn Leu Ser Leu Val
305 310 315

Cys Leu Asp Ser Ala Ser Ala Pro Arg Ser Val Ala Val Ser Ser
320 325 330

Ile Ala Gly Ser Thr Glu Leu Leu Val Thr Trp Gln Pro Gly Pro
335 340 345

Gly Glu Pro Leu Glu His Val Val Asp Trp Ala Arg Asp Gly Asp
350 355 360

Pro Leu Glu Lys Leu Asn Trp Val Arg Leu Pro Pro Gly Asn Leu
365 370 375

Ser Ala Leu Leu Pro Gly Asn Phe Thr Val Gly Val Pro Tyr Arg
380 385 390

Ile Thr Val Thr Ala Val Ser Ala Ser Gly Leu Ala Ser Ala Ser
395 400 405

Ser Val Trp Gly Phe Arg Glu Glu Leu Ala Pro Leu Val Gly Pro
410 415 420

Thr Leu Trp Arg Leu Gln Asp Ala Pro Pro Gly Thr Pro Ala Ile
425 430 435

Ala Trp Gly Glu Val Pro Arg His Gln Leu Arg Gly His Leu Thr
440 445 450

His Tyr Thr Leu Cys Ala Gln Ser Gly Thr Ser Pro Ser Val Cys
455 460 465

Met Asn Val Ser Gly Asn Thr Gln Ser Val Thr Leu Pro Asp Leu
470 475 480

Pro Trp Gly Pro Cys Glu Leu Trp Val Thr Ala Ser Thr Ile Ala
485 490 495

Gly Gln Gly Pro Pro Gly Pro Ile Leu Arg Leu His Leu Pro Asp
500 505 510

Asn Thr Leu Arg Trp Lys Val Leu Pro Gly Ile Leu Phe Leu Trp
515 520 525

Gly Leu Phe Leu Leu Gly Cys Gly Leu Ser Leu Ala Thr Ser Gly
530 535 540

Arg	Cys	Tyr	His	Leu	Arg	His	Lys	Val	Leu	Pro	Arg	Trp	Val	Trp
				545					550					555
Glu	Lys	Val	Pro	Asp	Pro	Ala	Asn	Ser	Ser	Ser	Gly	Gln	Pro	His
				560					565					570
Met	Glu	Gln	Val	Pro	Glu	Ala	Gln	Pro	Leu	Gly	Asp	Leu	Pro	Ile
				575					580					585
Leu	Glu	Val	Glu	Glu	Met	Glu	Pro	Pro	Pro	Val	Met	Glu	Ser	Ser
				590					595					600
Gln	Pro	Ala	Gln	Ala	Thr	Ala	Pro	Leu	Asp	Ser	Gly	Tyr	Glu	Lys
				605					610					615
His	Phe	Leu	Pro	Thr	Pro	Glu	Glu	Leu	Gly	Leu	Leu	Gly	Pro	Pro
				620					625					630
Arg	Pro	Gln	Val	Leu	Ala									
				635										

<210> 2

<211> 623

<212> PRT

<213> Mus musculus

<400> 2

Met	Asn	Arg	Leu	Arg	Val	Ala	Arg	Leu	Thr	Pro	Leu	Glu	Leu	Leu
1					5					10				15

Leu	Ser	Leu	Met	Ser	Leu	Leu	Leu	Gly	Thr	Arg	Pro	His	Gly	Ser
					20				25					30

Pro	Gly	Pro	Leu	Gln	Cys	Tyr	Ser	Val	Gly	Pro	Leu	Gly	Ile	Leu
					35				40					45

Asn	Cys	Ser	Trp	Glu	Pro	Leu	Gly	Asp	Leu	Glu	Thr	Pro	Pro	Val
					50				55					60

Leu	Tyr	His	Gln	Ser	Gln	Lys	Tyr	His	Pro	Asn	Arg	Val	Trp	Glu
					65				70					75

Val	Lys	Val	Pro	Ser	Lys	Gln	Ser	Trp	Val	Thr	Ile	Pro	Arg	Glu
					80				85					90

Gln	Phe	Thr	Met	Ala	Asp	Lys	Leu	Leu	Ile	Trp	Gly	Thr	Gln	Lys		
													95	100	105	
Gly	Arg	Pro	Leu	Trp	Ser	Ser	Val	Ser	Val	Asn	Leu	Glu	Thr	Gln		
														110	115	120
Met	Lys	Pro	Asp	Thr	Pro	Gln	Ile	Phe	Ser	Gln	Val	Asp	Ile	Ser		
														125	130	135
Glu	Glu	Ala	Thr	Leu	Glu	Ala	Thr	Val	Gln	Trp	Ala	Pro	Pro	Val		
														140	145	150
Trp	Pro	Pro	Gln	Lys	Ala	Leu	Thr	Cys	Gln	Phe	Arg	Tyr	Lys	Glu		
														155	160	165
Cys	Gln	Ala	Glu	Ala	Trp	Thr	Arg	Leu	Glu	Pro	Gln	Leu	Lys	Thr		
														170	175	180
Asp	Gly	Leu	Thr	Pro	Val	Glu	Met	Gln	Asn	Leu	Glu	Pro	Gly	Thr		
														185	190	195
Cys	Tyr	Gln	Val	Ser	Gly	Arg	Cys	Gln	Val	Glu	Asn	Gly	Tyr	Pro		
														200	205	210
Trp	Gly	Glu	Trp	Ser	Ser	Pro	Leu	Ser	Phe	Gln	Thr	Pro	Phe	Leu		
														215	220	225
Asp	Pro	Glu	Asp	Val	Trp	Val	Ser	Gly	Thr	Val	Cys	Glu	Thr	Ser		
														230	235	240
Gly	Lys	Arg	Ala	Ala	Leu	Leu	Val	Trp	Lys	Asp	Pro	Arg	Pro	Cys		
														245	250	255
Val	Gln	Val	Thr	Tyr	Thr	Val	Trp	Phe	Gly	Ala	Gly	Asp	Ile	Thr		
														260	265	270
Thr	Thr	Gln	Glu	Glu	Val	Pro	Cys	Cys	Lys	Ser	Pro	Val	Pro	Ala		
														275	280	285
Trp	Met	Glu	Trp	Ala	Val	Val	Ser	Pro	Gly	Asn	Ser	Thr	Ser	Trp		
														290	295	300
Val	Pro	Pro	Thr	Asn	Leu	Ser	Leu	Val	Cys	Leu	Ala	Pro	Glu	Ser		
														305	310	315

Ala Pro Cys Asp Val Gly Val Ser Ser Ala Asp Gly Ser Pro Gly
320 325 330

Ile Lys Val Thr Trp Lys Gln Gly Thr Arg Lys Pro Leu Glu Tyr
335 340 345

Val Val Asp Trp Ala Gln Asp Gly Asp Ser Leu Asp Lys Leu Asn
350 355 360

Trp Thr Arg Leu Pro Pro Gly Asn Leu Ser Thr Leu Leu Pro Gly
365 370 375

Glu Phe Lys Gly Gly Val Pro Tyr Arg Ile Thr Val Thr Ala Val
380 385 390

Tyr Ser Gly Gly Leu Ala Ala Ala Pro Ser Val Trp Gly Phe Arg
395 400 405

Glu Glu Leu Val Pro Leu Ala Gly Pro Ala Val Trp Arg Leu Pro
410 415 420

Asp Asp Pro Pro Gly Thr Pro Val Val Ala Trp Gly Glu Val Pro
425 430 435

Arg His Gln Leu Arg Gly Gln Ala Thr His Tyr Thr Phe Cys Ile
440 445 450

Gln Ser Arg Gly Leu Ser Thr Val Cys Arg Asn Val Ser Ser Gln
455 460 465

Thr Gln Thr Ala Thr Leu Pro Asn Leu His Ser Gly Ser Phe Lys
470 475 480

Leu Trp Val Thr Val Ser Thr Val Ala Gly Gln Gly Pro Pro Gly
485 490 495

Pro Asp Leu Ser Leu His Leu Pro Asp Asn Arg Ile Arg Trp Lys
500 505 510

Ala Leu Pro Trp Phe Leu Ser Leu Trp Gly Leu Leu Leu Met Gly
515 520 525

Cys Gly Leu Ser Leu Ala Ser Thr Arg Cys Leu Gln Ala Arg Cys
530 535 540

Leu His Trp Arg His Lys Leu Leu Pro Gln Trp Ile Trp Glu Arg
 545 550 555

Val Pro Asp Pro Ala Asn Ser Asn Ser Gly Gln Pro Tyr Ile Lys
 560 565 570

Glu Val Ser Leu Pro Gln Pro Pro Lys Asp Gly Pro Ile Leu Glu
 575 580 585

Val Glu Glu Val Glu Leu Gln Pro Val Val Glu Ser Pro Lys Ala
 590 595 600

Ser Ala Pro Ile Tyr Ser Gly Tyr Glu Lys His Phe Leu Pro Thr
 605 610 615

Pro Glu Glu Leu Gly Leu Leu Val
 620

<210> 3

<211> 2646

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 2433

<223> unknown base

<400> 3

gtgggttcgg cttcccggttg cgccctcgaaaa gctgtaccca gagctcgaag 50

aggagcagcg cggcccgacac ccggcaaggc tgggccggac tcggggctcc 100

cgagggacgc catgcgggaa ggcagggcgccc ttcttctg gctgtggccg 150

ctgccccaaac tggcgctgtt gcctctgttg tgggtgttt tccagcggac 200

gcgtccccaaac ggcagcgccg ggccactgca gtgctacggaa gttggaccct 250

tgggcgactt gaactgctcg tgggagcctc ttggggaccc gggagcccc 300

tccgagttac acctccagag ccaaaaagtac cggttccaaaca aaacccagac 350

tgtggcagtg gcagccggac ggagctgggt ggccatttcct cggaaacagc 400

tcaccatgtc tgacaaaactc cttgtctggg gcactaaggc aggccagcct 450

ctctggcccc ccgtcttcgt gaacctagaa acccaaatga agccaaacgc 500
cccccgctg ggccctgacg tggactttc cgaggatgac cccctggagg 550
ccactgtcca ttggggccca cctacatggc catctataa agttctgatc 600
tgccagttcc actaccgaag atgtcaggag gcggcctgga ccctgctgga 650
accggagctg aagaccatac ccctgaccac tggtgagatc caagatttg 700
agctagccac tggctacaaa gtgtatggcc gctgccggat ggagaaagaa 750
gaggatttgt gggcgagtg gagccccatt ttgtccttcc agacaccgccc 800
ttctgctcca aaagatgtgt ggttatcagg gaacctctgt gggacgcctg 850
gaggagagga acctttgctt ctatggaagg ccccaggggcc ctgtgtgcag 900
gtgagctaca aagtctggtt ctggggttggga ggtcgtgagc tgagtccaga 950
aggaattacc tgctgctgt ccctaattcc cagtggggcg gagtgggcca 1000
gggtgtccgc tgtcaacgcc acaagctggg agcctctcac caacctctct 1050
ttggtctgt tgatttcagc ctctgcccc cgtacgtgg cagtcagcag 1100
catcgctggg agcacggagc tactggtgac ctggcaaccg gggcctgggg 1150
aaccacttgg acatgttagtg gactgggctc gagatgggg accccctggag 1200
aaactcaact gggccggct tccccctggg aacctcagtg ctctgttacc 1250
aggaaatttc actgtcgggg tcccctatcg aatcactgtg accgcagtct 1300
ctgcttcagg ctggcctct gcacccctccg tctgggggtt cagggaggaa 1350
tttagcacccc tagtggggcc aacgcattttgg cgactccaaag atgcccctcc 1400
agggacccccc gccatagcgt ggggagaggt cccaaaggcac cagttcgag 1450
gccacccctcac ccactacacc ttgtgtgcac agagtggAAC cagccctcc 1500
gtctgcataa atgtgagttgg caacacacag agtgcacccc tgcctgaccc 1550
tccttgggtt ccctgtgagc tggtgggtgac agcatctacc atcgctggac 1600

agggccctcc tggtcccatc ctccggcttc atctaccaga taacaccctg 1650
aggtaaaag ttctgccggg catcctattc ttgtgggct tgttcctgtt 1700
gggtgtggc ctgagcctgg ccacctctgg aaggtgctac cacctaaggc 1750
acaaagtgt gccccgtgg gtctgggaga aagttcctga tcctgccaac 1800
agcagttcag gccagccccca catggagcaa gtacctgagg cccagcccc 1850
tggggacttg cccatcctgg aagtggagga gatggagccc ccgcgggtta 1900
tggagtccctc ccagcccgcc caggccaccg ccccgcttga ctctgggtat 1950
gagaagcact tcctgcccac acctgaggag ctgggccttc tggggccccc 2000
caggccacag gttctggcct gaaccacacg tctggctggg ggctgccagc 2050
caggctagag ggatgctcat gcaggttgca ccccagtcct ggattagccc 2100
tcttcatggaa tgaagacact gaggactcag agaggctgag tcacttacct 2150
gaggacaccc agccaggcag agctgggatt gaaggacccc tatagagaag 2200
ggcttggccc ccatgggaa gacacggatg gaaggtggag caaaggaaaa 2250
tacatgaaat tgagagtggc agctgcctgc caaaatctgt tccgctgtaa 2300
cagaactgaa tttggacccc agcacagtgg ctcacgcctg taatcccagc 2350
actttggcag gccaagggtgg aaggatcaact tagagctagg agtttgagac 2400
cagcctggc aatatagcaa gaccctcac taaaataaaata aaacatcaaa 2450
aacaaaaaca attagctggg catgatggca cacacctgta gtccgagcca 2500
cttgggaggc tgaggtggga ggatcggttg agcccaggag ttcgaagctg 2550
cagggacctc tgattgcacc actgcactcc aggctggta acagaatgag 2600
accttatctc aaaaataaaac aaactaataa aaaaaaaaaa aaaaaaa 2646

<210> 4
<211> 2005
<212> DNA
<213> Mus musculus

<400> 4
tcggtttat cgatggggcc atgaaccggc tccgggttgc acgcctcacg 50
ccgttggagc ttctgctgtc gctgatgtcg ctgctgctcg ggacgcggcc 100
ccacggcagt ccaggcccac tgcaagtgcata cagcgtcggt cccctggaa 150
tcctgaactg ctcctggaa cctttggcg acctggagac tccacctgtg 200
ctgtatcacc agagtcagaa ataccatccc aatagagtct gggaggtgaa 250
ggtgtccttcc aaacaaagtt gggtgaccat tccccggaa cagttcacca 300
tggctgacaa actcctcatc tgggggacac aaaaggacg gcctctgtgg 350
tcctctgtct ctgtgaacct ggagacccaa atgaagccag acacaccta 400
gatcttctct caagtggata tttctgagga agcaaccctg gaggccactg 450
tgcagtgggc gccgcccgtg tggccaccgc agaaagctct cacctgtcag 500
ttccggtaca aggaatgcca ggctgaagca tggacccggc tggagcccca 550
gctgaagaca gatgggctga ctcctgttga gatgcagaac ctggAACCTG 600
gcacctgcta ccaggtgtct ggccgctgcc aggtggagaa cggatatcca 650
tggggcgagt ggagttcgcc cctgtccttc cagacgccat tcttagatcc 700
tgaagatgtg tgggtatcgg ggaccgtctg tgaaacttct ggcaaacggg 750
cagccctgct tgtctggaaag gacccaagac cttgtgtgca ggtgacttac 800
acagtctggc ttggggctgg agatattact acaactcaag aagaggtccc 850
gtgctgcaag tcccctgtcc ctgcattggat ggagtggct gtggctctc 900
ctggcaacag caccagctgg gtgcctccca ccaacctgtc tctgggtgtc 950
ttggctccag aatctgcccc ctgtgacgtg ggagtgagca gtgctgatgg 1000
gagcccaggg ataaaggta cctggaaaca agggaccagg aaaccattgg 1050
agtatgtggc ggactggct caagatggc acagcctggc caagctcaac 1100
tggaccggc tcctccctgg aaacctcagc acattgttac cagggagtt 1150

caaaggaggg gtcccctatc gaattacagt gactgcagta tactctggag 1200
gattagctgc tgcaccctca gtttggggat tcagagagga gtttagtaccc 1250
cttgctgggc cagcagtttgc gcgacttcca gatgacccccc cagggacacc 1300
tgtttagcc tggggagaag taccaagaca ccagctcaga ggccaggcta 1350
ctcaactacac cttctgcata cagagcagag gcctctccac tgtctgcagg 1400
aacgtgagca gtcaaaccac gactgccact ctgccccacc ttcaactcgaa 1450
ttccttcaag ctgtgggtga cggtgtccac cgttgcagga cagggccac 1500
ctggtcccgaa cctttcactt cacctaccag ataataggat caggtggaaa 1550
gctctgcctt ggtttctgtc cctgtgggtt ttgcttctga tgggctgtgg 1600
cctgagcctg gccagtagcca ggtgcctaca ggccaggtgc ttacactggc 1650
gacacaagtt gcttccccag tggatctggg agagggttcc tgatcctgcc 1700
aacagcaatt ctgggcaacc ttacatcaag gaggtgagcc tgccccacc 1750
gcccaaggac ggaccatcc tggaggtgga ggaagtggag ctacagcctg 1800
ttgtggagtc ccctaaagcc tctgccccga tttactctgg gtatgagaaa 1850
cacttcctgc ccacaccaga ggagctggc cttctagtct gatctgctta 1900
cggttaggg ctgtaccct atcttggct agacgttcta gagtcgaccg 1950
cagaagcttgc cccgccccatgg cccaaacttgc ttattgcagc ttataatgtt 2000
aaata 2005

<210> 5
<211> 20
<212> DNA
<213> Mus musculus

<400> 5
tggtctctcc tggcaacagc 20

<210> 6
<211> 20

<212> DNA
<213> Mus musculus

<400> 6
agccaaagcac accagagaca 20

<210> 7
<211> 21
<212> DNA
<213> Mus musculus

<400> 7
cagctgggtg cctccacca a 21

<210> 8
<211> 20
<212> DNA
<213> Mus musculus

<400> 8
atccgcaagc ctgtgactgt 20

<210> 9
<211> 18
<212> DNA
<213> Mus musculus

<400> 9
tcgggccagg gtgttttt 18

<210> 10
<211> 18
<212> DNA
<213> Mus musculus

<400> 10
ttccccggct cggtggcg 18

<210> 11
<211> 18
<212> DNA
<213> Mus musculus

<400> 11
tcgcgtctct gggaaagct 18

<210> 12
<211> 24
<212> DNA
<213> Mus musculus

<400> 12
tttaagccaa tgtatccgag actg 24

<210> 13
<211> 20
<212> DNA
<213> Mus musculus

<400> 13
cgccagcgtc ctcctcgtag 20

<210> 14
<211> 21
<212> DNA
<213> Mus musculus

<400> 14
caagcatttg catcgctatc a 21

<210> 15
<211> 19
<212> DNA
<213> Mus musculus

<400> 15
aatgcctttt gccggaagt 19


<210> 16
<211> 24
<212> DNA
<213> Mus musculus

<400> 16
acgaattgag aacgtgccca ccgt 24

530 Rec'd POWPTO 27 JUN 2002

Patent Docket P1748R1E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	Group Art Unit: NOT KNOWN
Frederic J. DeSauvage et al.	Examiner: NOT KNOWN
Serial No.: 10/088,950	
Filed: October 18, 2000	
For: MODULATION OF T CELL DIFFERENTIATION FOR THE TREATMENT OF T HELPER CELL MEDIATED DISEASES	<p style="text-align: center;">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p style="text-align: right;">June 20, 2002</p> <p> Aida Guiam</p>

TRANSMITTAL LETTER

BOX SEQUENCES
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Copy of Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US);
 2. Certificate Re: Sequence Listing; Response Under 37 CFR § 1.821(f) and (g);
 3. Paper Copy of Sequence Listing and Diskette.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: June 20, 2002

By: Atulya R. Agarwal
Atulya R. Agarwal, Ph.D.
Reg. No. 40,887
Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/088,950	Frederic J De Sauvage	P1748RIE
		INTERNATIONAL APPLICATION NO.
		PCT/US00/28827
		I.A. FILING DATE PRIORITY DATE
		10/18/2000
RECEIVED Genentech Inc 1 DNA Way South San Francisco, CA 94080-4990 JUN 17 2002 GENENTECH, INC. LEGAL DEPT.		
CONFIRMATION NO. 4737 371 FORMALITIES LETTER  *OC00000008234986*		

Date Mailed: 06/07/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Assignee Statement
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

CALENDAR DUE DATES

Notice to Comply
7 AUG 02

Due Date

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy

or compact disc, as required by 37 CFR 1.821(c).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/088,950	PCT/US00/28827	P1748R1E

FORM PCT/DO/EO/905 (371 Formalities Notice)